Apple Tree Partners leaps across the pond to launch a UK biotech looking to crack the secrets of dendritic cells
Once largely a mystery to researchers, the far-flung realm of cells in the immune system has emerged as a fruitful sandbox for drug developers. A new UK biotech is leaning on research into the growing role of dendritic cells in spurring immune responses, and US venture firm Apple Tree Partners is bankrolling its early efforts.
London-based Adendra Therapeutics launched Tuesday with $53 million from founding investor ATP and research out of the Francis Crick Institute looking to leverage new insights into how dendritic cells sic predatory T cells onto tumors — and their role in driving autoimmune disease.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.